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Abstract
Background: The involvement of Heat Shock Proteins (HSP) in cancer development and progression is a widely
debated topic. The objective of the present study was to evaluate the presence and expression of HSP60 and
HSP10 in a series of large bowel carcinomas and locoregional lymph nodes with and without metastases.
Methods: 82 Astler and Coller's stage C2 colorectal cancers, of which 48 well-differentiated and 34 poorly-
differentiated, were selected along with 661 lymph nodes, including 372 with metastases and 289 with reactive
hyperplasia only, from the same tumours. Primitive tumours and both metastatic and reactive lymph nodes were
studied; specifically, three different compartments of the lymph nodes, secondary follicle, paracortex and
medullary sinus, were also analysed. An immunohistochemical research for HSP60 and HSP10 was performed and
the semiquantitative results were analysed by statistical analysis to determine the correlation between HSPs
expression and 1) tumour grading; 2) degree of inflammation; 3) number of lymph nodes involved; 4) lymph node
compartment hyperplasia. Moreover, western blotting was performed on a smaller group of samples to confirm
the immunohistochemical results.
Results: Our data show that the expression of HSP60, in both primary tumour and lymph node metastasis, is
correlated with the tumoral grade, while the HSP10 expression is not. Nevertheless, the levels of HSP10 are
commonly higher than the levels of HSP60. In addition, statistical analyses do not show any correlation between
the degree of inflammation and the immunopositivity for both HSP60 and HSP10. Moreover, we find a significant
correlation between the presence of lymph node metastases and the positivity for both HSP60 and HSP10. In
particular, metastatic lymph nodes show a higher percentage of cells positive for both HSP60 and HSP10 in the
secondary follicles, and for HSP10 in the medullary sinuses, when compared with hyperplastic lymph nodes.
Conclusion: HSP60 and HSP10 may have diagnostic and prognostic significance in the management of this
tumour and their overexpression in tumoral cells may be functionally related to tumoral progression. We
hypothesise that their expression in follicular and medullary cells of lymph nodes may be induced by formation of
metastases. Further studies based on these observations could lead to a better understanding of the HSPs
involvement in colorectal cancer progression, as well as other neoplasms.
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Background
Heat shock proteins (HSP) are a family of molecules that
are highly conserved during evolution and involved in
many cellular functions, such as protein folding. Conse-
quently, their alteration may have multiple pathophysio-
logic effects and the number of papers studying their
expression in normal and pathologic conditions is con-
stantly increasing [1-3]. In particular, the role of a number
of HSPs, such as HSP27, -70, -72 and -90, during carcino-
genesis has already been widely investigated, in vivo and in
vitro, in many conditions, such as lung [4], breast [5],
esophageal [6] and ovarian [7] cancer, as well as osteosa-
rcoma [8], and lymphoblastic leukemia [9]. The data
obtained in these studies seems to suggest that this group
of HSPs may be useful as tools in the management of
primitive neoplasms. Some articles have also suggested a
possible relationship between HSP expression and lymph
node metastasis formation [10-15].
HSP60 and HSP10 are two chaperones that interact in a
two-step folding mechanism in the mitochondria of
prokaryotic and eukaryotic cells [16]. In addition, these
proteins may be involved in other cellular functions, such
as mediating specific tumour signals, but these roles are
not yet well understood [3]. In the last few years, our
research group has evaluated the presence and expression
of HSP60 and HSP10 in a series of carcinogenetic models,
such as the "dysplasia-carcinoma" sequences of uterine
exocervix [17,18], large bowel [18,19] and prostate [20].
These data have highlighted that these chaperones are
overexpressed during the carcinogenetic steps; in particu-
lar, they accumulate in the cytoplasm of dysplastic and
neoplastic cells, and their levels of expression increases in
the sequence leading from dysplasia towards carcinoma.
We have hypothesised that HSP60 and HSP10 might be
considered as new diagnostic and prognostic tools for
these cancers [21,22], being involved in the molecular
steps of carcinogenesis, analogously to what has already
been demonstrated with other tumours [23-28].
HSP10 was recently shown to be selectively expressed by
myelocyte and megakaryocyte precursors in normal
human bone marrow [29]. This feature disappears during
lineage maturation, and it was hypothesised that HSP10
might have another role during differentiation and/or
proliferation of those normal cellular lineages apart from
the co-chaperonin one, although the obtained results
could not explain this selective expression.
In view of these factors, in the present work the presence
and expression of HSP60 and HSP10 were studied in a
series of advanced large bowel carcinomas (LBC) with
lymph node metastases. In particular, we investigated
whether their expression was dependent on the grade of
differentiation of the tumour and presence of regional
lymph node metastasis. Moreover, we analysed the signif-
icance of the data to determine the correlation between
HSP expression and both degree of inflammation and
number of lymph nodes involved. Finally, three different
compartments of each reactive lymph node, the secondary
follicles (SF), the paracortex (PC) and the medullary
sinuses (MS), were examined; lymph nodes with metas-
tases (MLN) were compared with lymph nodes with reac-
tive hyperplasia (HLN) only, to determine any differences
in HSP60 and HSP10 expression.
Methods
Immunohistochemistry
82 LBC of Astler and Coller's stage C2, with locoregional
node metastases, were collected. 48 well-differentiated
(G1) carcinomas were compared with 34 poorly-differen-
tiated (G3) ones. The specimens were formalin-fixed and
paraffin-embedded. From each case, a 5 micra section of
both tumour infiltrating the bowel wall (Ti) and lymph
node with metastasis (Ni) were obtained. 10 specimens of
normal colonic mucosae were selected, from which 5
micra sections were obtained as controls.
From all the tumours collected, 661 lymph nodes were
selected and divided in two groups; the first comprising of
372 lymph nodes with metastases (MLN) and the second
of 289 lymph nodes with reactive hyperplasia (HLN)
only. A 5 micra section was obtained from each sample.
An immunostaining for HSP60 (monoclonal, SIGMA,
H4149, 1:400), and HSP10 (Polyclonal, StressGen, SPA-
110, 1:400) was performed on the Ti, Ni, MLN and HLN
sections, using an avidin-biotin complex kit (LSAB2,
DAKO, Cat. No. K677). A non-immune serum was run
concurrently as negative control. 3-3'-diaminobenzidine
(DAB chromogen solution, DAKO, Cat. No. K3467) was
used as develop chromogen. Nuclear counterstaining was
obtained using hematoxylin (DAKO, Cat. No. S2020).
Three independent observers (F.C., F.R. and L.M.) exam-
ined the specimens and performed a semiquantitative
analysis to evaluate the percentage of positive cells in 10
HPF. The mean of the triplicate observation data was used
for statistical analyses. Moreover, we semiquantified the
degree of inflammation (infiltrating lymphocytes) in each
tumoral specimen on a scale of 0–3 + (from absent to
strongly positive).
We analysed the significance of the data using the Student
"t" test (P < 0.05). A one-way "analysis of variance"
(ANOVA) was used to determine the correlation between
HSP expression and 1) tumour grading; 2) degree of
inflammation; 3) number of lymph nodes involved; 4)
lymph node compartment hyperplasia.BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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Western blotting
Biopsies from specimens of Ti were frozen in liquid nitro-
gen for molecular biology. Specifically, 10 G1 and 10 G3
specimens of both tumours and metastatic lymph nodes
were collected randomly, along with 4 biopsies of normal
colonic mucosae as controls.
20 µg of total tissue extracts in each lane and a protein
marker (Kaleidoscope prestained standard, Bio-Rad, Cat.
No 1610324) were separated by electrophoresis on dena-
turing 15% polyacrylamide slab gel (SDS-PAGE) and
transferred to a nitrocellulose membrane (Nitrocell Paper,
Bio-Rad, Cat. No 1620115). After 1 hour at room temper-
ature (RT) with a blocking buffer (5% low-fat dried milk
in TBST: 50 mM Tris-HCl pH 7,5, 150 mM NaCl, 0,1 %
Tween-20) under gentle shaking, the membrane was incu-
bated with anti-HSP60 primary antibody (monoclonal
mouse, SIGMA, H4149, 1:1000) overnight at 4°C. After
washings, the membrane was incubated with HRP-conju-
gated secondary antibody (anti-mouse, Pierce, 1:10000,
Cat. No 31432) for 1 hour at RT with shaking and the spe-
cific binding was detected using a chemiluminescent sub-
strate (SuperSignal West Pico Chemiluminescent
Substrate, Pierce, Cat. No 34080) for autoradiography.
The same membrane was stripped with a stripping buffer
(Restore TM Western Blot Stripping Buffer, Pierce, Cat. No
21059) and incubated with anti-HSP10 primary antibody
Graphics showing comparison between data obtained by  quantitative analyses of HSP60 (a) and HSP10 (b) positive  tumoral cells in G1 and G3 Ti and Ni Figure 2
Graphics showing comparison between data obtained by 
quantitative analyses of HSP60 (a) and HSP10 (b) positive 
tumoral cells in G1 and G3 Ti and Ni.
HSP60 positivity in carcinoma (arrow) but not in normal tis- sues (arrowhead) in specimens from both well differentiated  (a) and poorly differentiated (b) tumours (Magnification: 10×) Figure 1
HSP60 positivity in carcinoma (arrow) but not in normal tis-
sues (arrowhead) in specimens from both well differentiated 
(a) and poorly differentiated (b) tumours (Magnification: 
10×). A higher magnification (40×) shows that the positivity 
is diffuse into cytoplasm of tumoral cells of both G1 (c) and 
G3 (d) specimens; few positive interstitial (inflammatory) 
cells were scattered in the interposed stroma. HSP10 is also 
diffusely expressed by tumoral cells of both G1 (e) and G3 (f) 
LBC (Magnification: 10×). A higher magnification (40×) of 
both G1 (g) and G3 (h) shows that the positivity is mainly 
localised in the cytoplasm of neoplastic elements.BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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(polyclonal rabbit, StressGen, SPA-110, 1:2000), follow-
ing the procedures described above (secondary antibody:
anti-rabbit, Pierce, 1:20000 Cat. No 31462).
Results
HSP60 and HSP10 positivity in primitive versus metastatic 
tumours of different grade
HSP60 was present in 40 out of 48 (83.3%) Ti G1 (fig.
1a,c) and in 32 out of 34 (94.1%) Ti G3 LBC (fig. 1b,d),
while HSP10 was present in all examined specimens of Ti
of both G1 (fig. 1e,g) and G3 (fig. 1f,h) LBC. In these spec-
imens, both molecules were present in the cytoplasm of
neoplastic cells, and they were also rarely present in some
inflammatory elements scattered in the stroma. In partic-
ular, statistical analyses, we did not find any correlation
between the degree of inflammation and the immunopo-
sitivity for HSP60 (p > 0.05) and HSP10 (p > 0.1).
In addition, the percentage of HSP60 positive cells was
higher in the G3 group (mean: 70%) compared with the
G1 (mean: 35%) (fig. 2a), while a similar number of
HSP10 positive elements were present in both groups
(mean: respectively 74% and 75%) (fig. 2b). Normal epi-
thelium above the infiltrating neoplasms resulted com-
monly negative or with few scattered positive elements
(fig. 1b), similarly to what observed in the biopsies of nor-
mal colonic mucosae (data not shown). Statistical analy-
ses showed that the difference between the number of
HSP60 positive cells in G1 and G3 LBC was significant (p
< 0.0005), while statistic difference was not found in
HSP10 positivity (p > 0.05).
Fig. 2c shows that 28 out of 48 Ni of G1 LBC (58%) were
positive for HSP60 (fig. 3a), compared to 26 out of 34 Ni
of G3 CRC (76%) (fig. 3b). Fig. 2d shows that all Ni of
both G1 (fig. 3c) and G3 (fig. 3d) LBC were positive to
HSP10. Statistical analyses showed that the difference
between the number of HSP60 positive Ni in G1 and G3
LBC was significant (p < 0.01), while statistic difference
was not found for HSP10 positivity (p > 0.05). Both
HSP60 and HSP10 positivity was often co-localised
within vascular (fig. 3e) and nervous (fig. 3f) structures
invaded by neoplastic tissue in both Ti and Ni.
The results of the immunoblotting analyses were compa-
rable to the immunohistochemical data (fig. 4). The
quantity of HSP60 was higher in G3 specimens of both Ti
and Ni, when compared to G1. HSP10 was present in a
similar amount in all examined specimens. Specimens of
normal colonic tissue were commonly under the thresh-
old of detectability for both HSP60 and HSP10.
HSP60 and HSP10 positivity in metastatic versus 
hyperplastic lymo nodes
We selected 661 lymph nodes from all the tumours
(mean: 8.1; range: 5–12; S.D. 2.2) and divided in two
groups; the first comprising of 372 MLN and the second
289 HLN. Firstly, we examined the presence of a statistic
correlation between HSPs expression and number lymph
node involved by the disease. We found the presence of a
significant correlation between the presence of metastases
and the positivity for both HSP60 (p < 0.005) and HSP10
(p < 0.001) in lymph nodes.
Western blot analyses for the research of HSP60 and HSP10  in tissue extracts of normal colonic mucosa (1), Ti G1 (2), Ti  G3 (3), Ni G1 (4) and Ni G3 (5) Figure 4
Western blot analyses for the research of HSP60 and HSP10 
in tissue extracts of normal colonic mucosa (1), Ti G1 (2), Ti 
G3 (3), Ni G1 (4) and Ni G3 (5).
Infiltrated lymph nodes from G1 (a) and G3 (b) LBC show  tumoral glands positive for HSP60 Figure 3
Infiltrated lymph nodes from G1 (a) and G3 (b) LBC show 
tumoral glands positive for HSP60. Metastases also show 
glands positive for HSP10 in both G1 (c) and G3 (d) carcino-
mas (Magnification: 40×). HSP60 positivity shows vascular (e) 
and neural (f) invasion by cancer (Magnification: 10×).BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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Subsequently, a semiquantitative analysis on the immu-
nohistochemical observations in the lymph node com-
partments of HLN was performed. Table 1 summarizes
these results. In SF cells of the HLN group, only 5% were
positive for HSP60 and 13% for HSP10. On the contrary,
we found an increase in the number of HSP60 (28%) and
HSP10 (35%) positive cells in SF of MLN (fig. 5a). We also
found a great increase in the number of HSP10 positive
cells in MS cells (38%) of MLN when compared to the
HLN group (3%). There was no significant difference in
the number of HSP60 positive cells between both HLN
and MLN groups in MS (fig. 5b), similarly to the number
of cells positive to both chaperones in PC of both HLN
and MLN groups (fig. 5c). Statistical analyses showed a
significant difference between the number of HSP60 pos-
itive cells in SF of the HLN and MLN groups (p < 0.0003).
Analogously, the number of HSP10 positive cells in both
SF (p < 0.001) and MS (p < 0.0001) presented a significant
difference. The positivity for both HSP60 (fig. 6a) and
HSP10 (fig. 6b) in the cells of all reactive lymph node
compartments was commonly localised in the cytoplasm.
Discussion
Although HSPs were first defined as proteins induced by
environmental and pathophysiologic stress, they are also
implicated in protein-protein interactions, such as fold-
ing, translocation, and prevention of inappropriate pro-
tein aggregation. Recently, other functions concerning
their pivotal roles during cancer development and pro-
gression have been suggested (30).
In a study conducted on a series of esophageal squamous
cell carcinomas, the overexpression of HSP70 was corre-
lated with lymph node metastasis, and lymphatic vessel
invasion, and the authors suggested that HSP70 expres-
sion might be used to assess the clinical outcome after sur-
gery [12]. A reduced expression of HSP70 and HSP40 has
also been associated with a lower histopathologic differ-
entiation in a series of gastric carcinomas [31]. In addi-
tion, Hwang et al. [13] have demonstrated that the
expression of HSP70 and HSP110 was increased in highly
metastatic colorectal cancer cell lines, but not in weak
metastatic cells, suggesting that the expression of these
HSPs is highly correlated with the advanced clinical stages
and positive lymph node involvement. In multivariate
analyses concerning the type, grade, stage of the tumour,
invasion of lymphatics, blood vessels and nerves as well as
lymph nodes, in 36 pancreatic adenocarcinomas, HSP70
immunoexpression was found to be an independent
prognostic factor [32]. Finally, in an immunohistochemi-
cal study on 102 esophageal squamous cell carcinoma
specimens Kawanishi et al. [33] suggested that the expres-
sion of HSP27 and HSP70 was frequently reduced and
therefore it should be considered an independent prog-
nostic factor in this disease.
In their study on primary invasive ductal carcinomas of
the breast with lymph node metastasis, Storm et al. [11]
found that HSP27 might confer cytoprotection for meta-
static cells, and they postulated that HSP27 overexpres-
sion is associated with reduced disease-free survival in
breast carcinomas. Contrastingly, Tetu et al. [34] did not
find any predictive role for HSP27 in the outcome in
node-positive breast carcinomas.
Piselli et al. [35] recently performed a cytofluorimetric
analysis on human pancreatic adenocarcinoma cells, both
grown in vitro and collected ex vivo from primary
tumours or lung metastases of tumour-engrafted SCID
mice; they were the first to demonstrate an HSP60 surface
expression on metastatic cells, but this expression was not
correlated with metastasization. In a multivariate analysis
on a series of metastatic breast cancers, Schneider et al.
[36] demonstrated that neither HSP27 nor HSP60 expres-
sion was able to exclude axillary node invasion com-
pletely. Finally, Ito et al. [37] studied the expression of
HSP27, -60, -70 and -90 in 24 squamous cell carcinomas
of the tongue using immunohistochemistry, finding that
HSP immunoexpression might change during tumorigen-
esis, but there was no correlation between HSP staining
and survival period, clinical stage, lymph node metastasis,
histological grade or p53 immunostaining.
Table 1: Mean percentages and ranges of immunopositive cells
HLN PART MEAN RANGE MLN PART MEAN RANGE
SF 5% 0–8% SF 28% 7–41%
HSP60 PC 2% 0–4% HSP60 PC 2% 0–4%
MS 1% 0–2% MS 3% 0–6%
SF 13% 4–22% SF 35% 18–58%
HSP10 PC 5% 2–8% HSP10 PC 9% 4–19%
MS 3% 1–5% MS 38% 22–65%
Mean percentages and ranges of immunopositive cells in hyperplastic lymph nodes (HLN), left side, and metastatic lymph node (MLN), right side. SF: 
secondary follicles; PC: paracortex; MS: medullary sinuses. See text for more details.BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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As far as we are aware, the present work is the first study
reporting the expression of HSP60 and HSP10 in a series
of LBC with lymph node metastases, and the immunolo-
calisation of these molecules in the different compart-
ments of reactive lymph nodes.
The presence and expression of HSP60 and HSP10 in
some carcinogenic models, in particular, both pre-
tumoral (dysplastic) and neoplastic lesions of large
bowel, as well as uterine exocervix and prostate gland has
been investigated previously [17-20]. These experiments
showed that the level of these two strictly related mito-
chondrial chaperonins increases from normal through
dysplastic towards neoplastic tissues. These proteins
resulted diffusely localised in the cytoplasms of dysplastic
and neoplastic cells. Moreover, few scattered inflamma-
tory elements were occasionally positive at stromal level.
Considering this overexpression, it was hypothesised that
these molecules might have different functions during
cancer development, apart from the mitochondrial regen-
eration during normal cell proliferation. Nevertheless, the
exact nature of this role is still not understood.
In the present paper, the expression of HSP60 in Ti and Ni
was found to be dependent on the tumoral grade, while
the expression of HSP10 was not. The number of HSP60
positive tumoral cells in Ti of G3 LBC was higher than in
G1, and the number of HSP60 positive Ni in G3 LBC was
higher than in G1. Immunohistochemical results were
confirmed by immunoblotting analysis. Therefore, we
postulate a prognostic significance of these data. HSP10
was strongly positive in all examined specimens, and
these results may have a diagnostic utility. Interestingly, a
higher positivity for HSP60, but not for HSP10, was corre-
lated with the presence of lymph node metastasis and this
data may have a histopathologic value.
Although normal epithelia periodically regenerate cellular
elements by mitosis of basal cells, the present work shows
that HSP60 and HSP10, in normal epithelia, are under the
antibody detection threshold for immunohistochemical
analyses, while neoplastic elements show a strong cyto-
plasmic expression of these proteins. Many papers have
already shown the involvement of the HSP60/HSP10
complex in preventing the activation of the apoptotic
machinery. Samali et al [38] were the first to demonstrate
that pro-caspase-3 is present in the mitochondrial fraction
of Jurkat T cells in a complex with the chaperon proteins
HSP60 and HSP10 and that the release of mitochondrial
HSP may also accelerate caspase activation in the cyto-
plasm of intact cells. These data are in accordance with the
findings of Xanthoudakis et al. [39] who showed that
ATP-dependent 'foldase' activity of HSP60 may induce
High magnifications (100×) of immunostaining for HSP60 (a)  and HSP10 (b) show cytoplasmic positivity Figure 6
High magnifications (100×) of immunostaining for HSP60 (a) 
and HSP10 (b) show cytoplasmic positivity.
Diagrams showing the differences of the mean number of  positive cells between HLN and MLN in the lymph node  compartments: a) secondary follicles; b) paracortex; c) med- ullary sinuses Figure 5
Diagrams showing the differences of the mean number of 
positive cells between HLN and MLN in the lymph node 
compartments: a) secondary follicles; b) paracortex; c) med-
ullary sinuses.BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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pro-caspase-3 maturation in Jurkat cells stimulated to
undergo apoptosis by a Fas-independent pathway and
that this represents an important regulatory event in
apoptotic cell death. Lin et al. [40] suggested that overex-
pression of the combination of HSP60 and HSP10 and of
HSP60 or HSP10 individually may protect myocytes
against apoptosis in an in vitro model of ischemia/reper-
fusion injury. More recently they have demonstrated that
HSP10 overexpression may inactivate Raf, ERK, and
p90Ribosomal kinase (p90RSK), suggesting that only
HSP10 is involved in the complex mechanisms that pro-
tect myocytes against simulated ischemia and reoxygena-
tion induced death.
We could postulate that both HSP60 and HSP10 are up-
regulated in cancer for extramitochondrial functions, i.e.
in the block of the apoptotic machinery that usually takes
place during cancer development and progression.
Although HSP60 and HSP10 should be functionally cor-
related, HSP10 is present in a higher number of specimens
and with a higher expression than HSP60. This result may
indicate a different function of HSP10 inside the cyto-
plasm of tumoral cells. In a recent study, where the expres-
sion of HSP10 and HSP60 was investigated in a series of
normal human bone marrows, similar data were found
[29]. Interestingly, a selective preference of HSP10 for
myeloid and megakaryocytic precursors was discovered
[29]. Therefore, other roles of HSP10 apart from the co-
chaperonin one during bone marrow cell proliferation
and differentiation of normal cells could be hypothesised.
This is backed up by other studies on this co-chaperonin
[41,42].
In the present study, the presence and localisation of
HSP60 and HSP10 in a series of human lymph nodes were
evaluated. Lymph node functioning is crucial for an indi-
vidual's survival. Normal lymph nodes are very small
structures, not always clinically detectable in human
body. They react to antigens by uptaking and processing
them, eventually destroying them. Reacting lymph nodes
enlarge due to immunologic stimulation that drives their
hyperplasia. Examining a histological section of hyper-
plastic lymph node, different compartments can be distin-
guished: 1) the follicles, where precursors of plasma cells
and memory B cells are formed; 2) paracortex, where spe-
cific cellular response takes place, generating antigen-spe-
cific T cells; 3) medullar sinuses, where the lymph carried
from afferent to efferent lymphatic vessels is cleared by
macrophages [43-45]. Commonly, hyperplasia involves all
lymph node structures; as already demonstrated, in a
study on a wide series of HLN and MLN from axilla, the
most common pattern of hyperplasia is the mixed type
(66.5% of 996 HLN and 68.6% of 4711 MLN). In partic-
ular, hyperplasia mainly involved both follicles and para-
cortex area (22.2% of MLN and 19.2% of HLN), although
often sinuses were also found enlarged [46]. A fundamen-
tal step during the examination of an enlarged lymph
node is the distinction between a reactive hyperplasia and
a neoplasm. The latter may be of primary (lymphoma) or
secondary (metastasis) type. In an investigation on a
series of 1159 lymph nodes from breast cancer, microme-
tastases (involving less that 25% of the lymph nodal vol-
ume) have been shown often to be present also in very
small nodes (less that 2 mm in diameter) [47]. Unfortu-
nately, the detection of metastases in a lymph node is dif-
ficult if they are small in dimension. Several studies have
shown that a number of histologically negative lymph
nodes may present, at a retrospective analysis, a microme-
tastasis revealed only immunohistochemically or with
immunofluorescence techniques; the presence of
micrometastasis in the lymph node has great prognostic
and therapeutic implications [48-53].
In this study, the number of SF cells positive for both
HSP60 and HSP10 increased significantly in MLN, when
compared to HLN. We postulate that this increase may be
related to formation of metastases. As a consequence,
although cytokeratin staining is a much easier way to
detect micrometastasis, the statistically significant incre-
ment in the MLN group of the number of HSP60 and
HSP10 positive elements in secondary follicles could also
be considered diagnostic to predict the presence of lymph
node metastases. Therefore, a lymph node with germinal
centre presenting a strong staining for HSP60 and/or
HSP10 without any apparent metastasis should be exam-
ined in detail, since this observation may reflect an
increased likelihood of finding a micrometastasis.
Since MS of MLN showed a significantly higher amount of
HSP10, but not HSP60, positive cells, when compared to
the MS of HLN, we could assume that HSP10 in this site
is under unknown stimulation inducing its overexpres-
sion, for functional roles, i.e. cell proliferation. The role of
HSP60 during proliferation and differentiation of eukary-
otic cells has already been demonstrated [54-56]. Moreo-
ver, HSP60 and HSP10, working together, could protect
mitochondrial function and prevent apoptotic cell death
[37,39] although some studies have shown that these
molecules do not always act as a single functional unit in
vivo [41,57].
Conclusion
Many papers have been focusing on the role of some HSPs
to predict cancer progression [11-13,58]. We found partic-
ularly interesting the paper of Storm [11], who first
showed the expression of HSP27 in metastatic lymph
nodes to confer cytoprotection for metastatic cells of
breast carcinoma and its association with the reduced dis-
ease-free survival. In addition, a selective expression of
HSP70 in the germinal centres of HLN has been demon-BMC Cancer 2005, 5:139 http://www.biomedcentral.com/1471-2407/5/139
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strated, although the meaning of this overexpression is
not understood [59].
Our researches showed an overexpression of HSP60 and
HSP10 in LBC with lymph node metastases. Both mole-
cules could be useful for histopathologic diagnosis of this
neoplasm, as well as to better assess the prognosis. We
could also assume that both proteins are involved in LBC
progression, i.e. exercising an antiapoptotic effect. We
hypothesise that the increased expression of HSP60 and
HSP10 in reactive lymph node cells is due to their role in
proliferation of normal cells. Recently it has been shown
that HSP60 activates macrophages and T-cell, and this
could also be a possible explanation for its overexpression
in lymph nodes with metastatic cancer upregulation [60].
Based on these considerations, it could be postulated that
paracrine factors, such as cytokines, may induce an up-
regulation of these molecules, but the exact role of the
overexpression remains to be confirmed.
Serial sectioning could be used to further study if any of
the HLN population that present HSP60 and HSP10 stain-
ing in the range of MLN contain occult metastases; it
could also be interesting to compare HLN from LBC spec-
imens with non-neoplastic setting ones, i.e. resections of
active inflammatory bowel disease, to confirm whether
the former could be used as proper controls. Finally, the
selective overexpression of HSP10 in MS of MLN could
support the hypothesis that this molecule, following
unknown biological stimulations, acts independently
from HSP60.
In conclusion, our study could add new data to the classic
classification of G1 or G3, since both HSP60 and HSP10
positivity may help to detect more aggressive tumors.
Moreover, the comparison of the expression levels of
these chaperones with other predictors of survival, as
grading, number of metastatic lymph nodes and degree of
tumor infiltrating lymphocytes may be useful in colon
cancer management.
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